Orchestra BioMed Holdings, Inc. (OBIO) Research

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Market snapshot

Symbol
OBIO
Price
$3.99
Day change
+3.10%
Market cap
$238.9M
P/E ratio
-2.80x
52-week range
2.2-5.424
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$13.00

Peer companies

  • Avalo Therapeutics, Inc. (AVTX)
  • Caribou Biosciences, Inc. (CRBU)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Eupraxia Pharmaceuticals Inc. (EPRX)
  • Inventiva S.A. (IVA)
  • Invivyd, Inc. (IVVD)
  • Prelude Therapeutics Incorporated (PRLD)
  • Pyxis Oncology, Inc. (PYXS)

Recent insider activity

  • Taylor Andrew Lawrence — F-InKind (36352 shares) on 2026-06-10
  • Hochman David P — F-InKind (3283 shares) on 2026-06-10
  • Hochman David P — F-InKind (3283 shares) on 2026-06-10
  • Hochman David P — P-Purchase (5000 shares) on 2026-06-01
  • Sherman Darren — S-Sale (15000 shares) on 2026-06-01

Open Orchestra BioMed Holdings, Inc. (OBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.